|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
| |  |
Co-sponsored by NYAS,
Columbia
University Biotechnology
Association, and NYU Biotechnology Association:
Biotechnology and
Pharma: Evolution and Adaptation
Pharma and biotech provides us medicines and treatments that improve our lives, but these industries face significant challenges of decreased innovation and dwindling drug pipelines. Join us for an expert panel discussion that will address the impact of science, regulation, business and society on the current state of drug development and its designs for the future. Speakers: Ralph Marcello, Senior Manager, Deloitte Consulting LLP Alan E. Smith, EVP and CSO, Genzyme Robert A. Copeland, EVP and CSO, EpiZyme, Inc. Cole Werble, Editor-in-Chief, The RPM Report (Windhover Information, Inc.) Peter Vaccari, Orphan Products Program, FDA Andrew Marshall, Editor, Nature Biotechnology
The event is free for Columbia students; please register for the event at: http://www.nyas.org/sabiotech_affiliate
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
